First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker...
| Author | |
|---|---|
| Abstract |
:
Survival for patients with advanced gastroesophageal cancer (AGC) using standard treatment regimens is poor. EGFR overexpression is common in AGC and associated with poor prognosis. We hypothesized that increasing the dose intensity of chemotherapy and adding panitumumab could improve efficacy. |
| Year of Publication |
:
2017
|
| Journal |
:
Oncotarget
|
| Volume |
:
8
|
| Issue |
:
67
|
| Number of Pages |
:
111795-111806
|
| Date Published |
:
2017
|
| URL |
:
http://www.impactjournals.com/oncotarget/misc/linkedout.php?pii=22909
|
| DOI |
:
10.18632/oncotarget.22909
|
| Short Title |
:
Oncotarget
|
| Download citation |
